PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 163-168

  Atadja, Peter ^a   Watanabe, Toru ^b   Xu, Hong ^a   Cohen, Dalia ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Chemosensitization; Chemotherapy; Multidrug resistance

Indexed keywords

GLYCOPROTEIN P; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

ANIMALS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; RATS;

EID: 0031847511     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006046201497     Document Type: Review

References (28)

1. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I: Genetic analysis of the multidrug transporter. Ann Rev Gen 29: 607-649, 1995
2. Cobb PW, Rothenberg ML: PSC: A multidrug resistance modulating agent. DN&P 8: 475-479, 1995
3. Ford J, Hait W: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 156-199, 1993
4. Twentyman PR: Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br J Cancer 57: 254-258, 1988
5. Boesch D, Muller K, Poutier-Manzanendo A, Loor F: Restoration of daunomycin retention in multidrug resistant P388 cells by submicromolar concentrations of SDZ PSC 833. Exp Cell Res 196: 26-32, 1991
6. Twentyman PR, Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639-1642, 1991
7. Archinal Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D: Analysis of the interactions of SDZ PSC-833 ([3′keto-BMT1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995
8. Erlisch PH, Moustafa ZA, Archinal-Mattheis AE, Newman MJ, Bair KW, Cohen D: The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC-833. Anticancer Res 17: 129-134, 1997
9. Pinica-worms D, Rao VV, Kronauge JF, Croop JM: Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34: 12210-12220, 1993
10. Pinica-worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1995
11. Barbaries E, Kronauge J, Cohen D, Davison A, Jones AG, Croop JM: Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 58: 276-282, 1998
12. Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T: Modulation of multidrug resistance by SDZ PSC-833 in leukemic and solid-tumor-bearing mouse models. Jpn J Cancer Res 87: 184-193, 1996
13. Keller RP, Altermatt HJ, Donatcsh P, Zihlman H, Lasue JA, Hiestand PC: Pharmacologic interactions between the resistance modifying cyclosporine SDZPSC-833 and etoposide (VP16-213) enhance in vivo cytotoxic activity and toxicity. Int J Cancer 51: 433-438, 1992
14. Rohlf DP, et al.: Circumvention of the multidrug resistance gene product to enhance the chemoresponsiveness of renal cell carcinoma in a xenograft model. J Urology (Baltimore) 151 (Suppl 1): 338A, 1994
15. 185 to Val substitution in human P-glycoprotein on the reversal activity of PS-833. Proc Am Assoc Cancer Res 37: abstract # 227, 1996
16. Chen G, Duran GE, Lacayo NJ, Jaffrezou NJ, Dumonet C, Sikic BI: Multidrug resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype and resistance to cyclosporins. J Biol Chem 272: 5974-5982, 1997
17. Watanabe T, Kokuho N, Charnick SB, Naito M, Tsuruo T, Cohen D: Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. British J Pharmacol 122: 241-248, 1997
18. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C. Hensel S, Smyth JF, Brampton MH, Blechen NM: Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996
19. Dalton WS: Drug resistance modulation in the laboratory and the clinic Semin. Oncol 20: 64-69, 1993
20. Fisher GA, Sikic BI: Clinical studies with modulators of multidrug resistance. Hematol and Oncol Cin North Am 9: 363-382, 1995
21. Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J: A phase I trial of doxorubiein (D) and PSC833, a modulator of multidrug resistance (MDR). Proc ASCO 13: 134 abstract 330, 1994
22. Giacconne G, Linn SC, Catimel G, et al.: Phase I and pharmacokinetic study of SDZ PSC-833 per os in combination with doxorubicin in patients with solid tumors. Proc ASCO 14: 142 abstract 364, 1995
23. Collins HL, Fisher GA, Hausdorf J, Lum BL, Pearce T, Halsey J, Sikic B: Phase I trial of praclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc ASCO 325; 14: 181 abstract 406, 1995
24. Hausdorff J, Fisher GA, Hasley J, Collins HL, Lum BL, Brophy NA, Duran GE, Nix D, Pearce T, Sikic BI: A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc ASCO 14: 181 abstract 407, 1995
25. Sonneveld P, Lowenberg B, Vossebeld P, Malkhendi J, Covelli A, Deckker AW, Ossenkopela G, Muligan D, Verhoef G, Ferret A, Lin J, Gratwohl A, Kovcsovics T, Burnett A: Dose-finding study of PSC-833, a novel MDR reversing agent with daunorubicin and ARA-C in untreated elderly patients with acute myeloid leukemia (AML). Blood 90: (Suppl 1): abstract # 2517, 1997
26. Visani G, Milligan D, Leoani F, Chang J, Kelsy S, Marcus R, Powles R, Schey S, Covelli A: A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML). Blood 90: (Suppl 1): abstract # 2518, 1997
27. Advani R, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramej J, Dugan B, Lum B, Villena J, Sikic BI, Davis E, Paitta E, Litchman M, Greenberg P: Treatment of poor prognosis AML with PSC-833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Blood 90 (Suppl 1): abstract # 2260, 1997
28. Fields H, Hochster C, Runowiz C, Speyer J, Goldberg C, Cohen C, Dottino P, Wadler S, Back G, Gretz H, Mandeli J, Holland J, Letvak L: SDZ-PSC-833/paclitaxel in paclitaxel refractory ovarian carcinoma: A phase II trial with renewed responses. Proc ASCO abstract # 1254, 1997